← Leaderboards
Marc C. Levesque
Duke University
$4,161,424
Attributed
$6,196,328
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$6,196,328 · 7
By mechanism
RC2$2,872,161 · 1
R01$2,586,327 · 2
R21$421,589 · 1
R03$297,000 · 2
M01$19,251 · 1
Top collaborators
- Chester V Oddis4 shared
- Larry W Moreland3 shared
Most similar at Duke University
Same institution · by research overlap
- S Munir Alam$19,719,051
- Thomas B Kepler$37,171,109
- Paul Lawrence Modrich$12,490,868
- Mark C Lanasa$483,411
- Mary H Foster$6,787,316
Others in their field
Top investigators on “Rheumatoid Arthritis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Lionel B Ivashkiv · Hospital For Special Surgery$38,096,851
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- V Michael Holers · University Of Colorado Denver$28,178,502
- Michael B Brenner · Brigham And Women'S Hospital$26,598,289
- Betty Diamond · Feinstein Institute For Medical Research$20,428,564
Research focus
Rheumatoid ArthritisBloodFundingLaboratoriesBiologicalEffectivenessSpecimenBaseMediatingLeadPublic Health RelevanceImmuneNitric OxideAutoimmune DiseasesPeripheral BloodMorbidity - Disease RateAdultCessation Of LifeMortality Vital StatisticsB-LymphocytesImmunoglobulinsFlow CytometryCytokineGenes
Grant awards (19)
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients$282,301
R01 · FY2013 · AR
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients$297,142
R01 · FY2012 · AR
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients$297,126
R01 · FY2011 · AR
Randomized observation study of biologic therapy for rheumatoid arthritis$1,366,857
RC2 · FY2010 · AR
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients$321,078
R01 · FY2010 · AR
Randomized observation study of biologic therapy for rheumatoid arthritis$164,718
RC2 · FY2010 · AR
Randomized observation study of biologic therapy for rheumatoid arthritis$1,340,586
RC2 · FY2009 · AR
Prevention of Chronic Lymphocytic Leukemia (CLL)$78,000
R03 · FY2008 · CA · contact PI
Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants$227,214
R21 · FY2007 · AI · contact PI
Prevention of Chronic Lymphocytic Leukemia (CLL)$78,000
R03 · FY2007 · CA · contact PI
Nitric Oxide Metabolism in Statin-treated Pediatric SLE$303,424
R01 · FY2006 · AR · contact PI
Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants$194,375
R21 · FY2006 · AI · contact PI
Nitric Oxide Metabolism in Statin-treated Pediatric SLE$356,165
R01 · FY2005 · AR
NITRIC OXIDE, LPS AND THE PATHOGENESIS OF ASTHMA$18,829
M01 · FY2005 · RR
Nitric Oxide Metabolism in Statin-treated Pediatric SLE$363,498
R01 · FY2004 · AR
Nitric Oxide, LPS and the Pathogenesis of Asthma$422
M01 · FY2004 · RR
Nitric Oxide Metabolism in Statin-treated Pediatric SLE$365,593
R01 · FY2003 · AR
HYALURONAN-MEDIATED NITRIC OXIDE PRODUCTION BY MACROPHAG$70,500
R03 · FY2001 · AR
HYALURONAN-MEDIATED NITRIC OXIDE PRODUCTION BY MACROPHAG$70,500
R03 · FY2000 · AR